The startup develops genome-based therapeutics utilizing fungal metabolites to address psychiatric and neurological disorders. By researching various fungal species, the company aims to enhance drug development for medical professionals, promoting the therapeutic potential of fungi for human health.
Funding
$63.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing treatments for neuropsychiatric disorders like Premenstrual Dysphoric Disorder (PMDD), Obsessive Compulsive Disorder (OCD), and Opioid Use Disorder (OUD) often provide only partial relief and raise tolerability concerns. This unmet need underscores the importance of finding safe and efficacious treatment alternatives, especially considering the high comorbidity of these disorders with major depression and the elevated risk of suicide.
Solution
MycoMedica Life Sciences is a biopharmaceutical company focused on developing psilocybin-based medications for mental health and neurodegenerative disorders. The company is conducting non-clinical and clinical studies to understand the neurochemistry and behavioral pharmacology of psilocybin. MycoMedica utilizes a novel dosing paradigm to optimize pharmacology, maximize patient access, and reduce the burden on patients and providers. Their approach involves researching 5HT2A receptor-targeted treatments to drive clinically meaningful improvements and better outcomes for patients.
Target Audience
The primary target audience includes individuals suffering from neuropsychiatric disorders such as PMDD, OCD, and OUD, as well as medical professionals seeking new treatment options for these conditions.
Features
- Focus on psilocybin-based treatments for neuropsychiatric conditions.
- Conducting non-clinical studies to understand the neurochemistry and behavioral pharmacology of psilocybin in animals.
- Human clinical studies to test the safety and efficacy of low-dose psilocybin treatments.
- Prioritized Premenstrual Dysphoric Disorder (PMDD) as the first clinical trial.
- Researching the science underlying 5HT2A receptor-targeted treatments.
- Developing treatments for Obsessive Compulsive Disorder (OCD) and Opioid Use Disorder (OUD).
- Exploring potential treatments for neurodegenerative conditions such as Parkinson's Disease (PD).